Prostate Cancer Survival Rates Improved Since Introduction of PSA Testing
Survival Rate for African American Men Now Comparable to Caucasians, The Journal of Urology® Reports
Philadelphia, PA, August 23, 2012 – The routine use of prostate specific antigen (PSA) testing for screening and monitoring prostate cancer has led to early and more sensitive detection of the disease. A new study published in The Journal of Urology® reports that in the “PSA era,” survival has improved for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body and the disparity between African American and Caucasian men has been resolved.
“Our analysis indicates an overall improvement in risk adjusted survival rates for non-African American and African American men. Of note is the resolution of disparity in survival between the races found in earlier studies,” says lead investigator Ian M. Thompson, Jr., MD, Director of the Cancer Therapy and Research Center, a National Cancer Institute-Designated Cancer Center, and Professor in the Department of Urology at the UT Health Science Center at San Antonio, TX.
The Southwest Oncology Group, a National Cancer Institute (NCI) sponsored organization that conducts clinical trials in adult cancers, has performed a series of clinical trials over the last three decades that evaluated patient survival after androgen deprivation treatment (ADT) for prostate cancer. Two of the trials took place before, and one took place after the introduction of PSA screening. “These sequential trials provide an opportunity to address the question of whether survival has improved since the advent of widespread PSA screening and follow-up testing,” says Dr. Thompson. Patient populations and eligibility criteria were comparable across the three studies, which enrolled patients from cancer centers around the country. Patients in all three trials received similar ADT treatments.
Median survival in trial S8494, which enrolled patients from 1985 to 1986, was 30 months, and median survival in trial S8894, which enrolled patients from 1989 to 1994, was 33 months. In contrast, median survival in trial S9346, which enrolled patients from 1995 to 2009, was 49 months. A 30% decreased risk of death was found in the most recent trial (S9346) from the previous trial (S8894).
The interaction of various risk factors, such as extensive versus minimal disease, older age, race, and body mass index was assessed. In S8494 the median survival for African American men was 27 months, while in S9346, the survival rate was 48 months, which is very close to that of white men.
Dr. Thompson notes that African American men had poorer results in the earlier studies despite receiving treatment in a carefully overseen clinical trial. “When we evaluated ZIP code summary information regarding income and education, there was no shift in socioeconomic status over time. We hypothesize that this improvement is based on greater awareness of prostate cancer and improved health seeking behavior in African American men.” However, African American men have a two- to three-fold greater incidence of newly diagnosed metastatic prostate cancer compared to white men, which contributes to a similarly increased mortality rate. “A greater effort is needed to eliminate disparities in prostate cancer,” he says.
Dr. Thompson concludes, “While not all of these welcome improvements can be attributed strictly to PSA testing, without a doubt it has played a role in extending many lives.”
# # #
Notes for editors
“Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346),” C.M. Tangen, M.H.A. Hussain, C.S. Higano et al. (DOI: 10.1016/j.juro.2012.06.046). It appears online in advance of publication in The Journal of Urology, Volume 188, Issue 4 (October 2012) published by Elsevier.
This SWOG investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102 and CA38926, and in part by AstraZeneca, and Merck & Co (previously Schering-Plough).
Full text of the article is available to credentialed journalists upon request; contact Linda Gruner at +1 216 633 3923 or firstname.lastname@example.org to obtain copies. To schedule an interview with the authors, please contact Elizabeth Allen, Media Communications Officer, The UT Health Science Center at San Antonio, at +1 210 450 2020 or email@example.com.
About The Journal of Urology®
Established in 1917, The Journal of Urology ( www.jurology.com) is the official journal of the American Urological Association ( www.auanet.org). It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. www.elsevier.com
+1 212 633 3923